期刊文献+

奥沙利铂磷脂复合物及其纳米混悬剂的制备 被引量:3

Preparation of oxaliplatin phospholipid complex and its nanosuspension
在线阅读 下载PDF
导出
摘要 目的研究奥沙利铂磷脂复合物及其纳米混悬液的制备方法。方法以奥沙利铂与磷脂的复合率为指标,采用单因素和正交试验设计优化了奥沙利铂磷脂复合物的制备工艺。采用逆相蒸发法结合高压均质技术,将奥沙利铂磷脂复合物制成纳米混悬液,并进行理化性质考察。结果奥沙利铂与磷脂的复合率可达100%。制备的纳米混悬液载药量提高到10 g.L-1,平均粒径为(126±17)nm,具有良好的物理稳定性。结论磷脂复合物改善了奥沙利铂的理化性质及溶解性能,用其制备的纳米混悬剂可静脉给药。 Objective To study the preparation methods for oxaliplatin phospholipid complex (OPPLC) and its nanosuspension. Methods The preparation conditions of OPPLC were optimized by single factor test and orthogonal design using binding ratio of oxaliplatin to phospholipid as evaluation parameter. The OPPLC nanosuspension was prepared by reverse-phase evaporation methods and high pressure homogenization and the physicochemical properties were studied. Results Oxaliplatin was complexed with phospholipid completely. The drug-loading rate of nanosuspension was 10 g · L^-1 and the mean particle size was ( 126 ± 17) nm. Good stability was also achieved. Conclusions The solubility and physicochemical properties of oxaliplatin were significantly improved by the prepared OPPLC. The nanosuspension enables the intravenous injection to be used in high dose with low toxicity and affords enhanced efficacy.
作者 刘伟 王东凯
出处 《沈阳药科大学学报》 CAS CSCD 北大核心 2007年第4期197-200,共4页 Journal of Shenyang Pharmaceutical University
关键词 奥沙利铂 磷脂复合物 纳米混悬液 理化性质 oxaliplatin phospholipid complex nanosuspension physicochemical properties
作者简介 刘伟(1972-),女(汉族),辽宁沈阳人,硕士研究生 王东凯(1962-),男(汉族),辽宁新民人,副教授,主要从事药剂学研究,Tel.024-23986963,E-mail:WangDKSY@126.com。
  • 相关文献

参考文献6

  • 1艾萍,金义光,王林校.药物传送中的纳米混悬液[J].国外医学(药学分册),2005,32(1):61-63. 被引量:9
  • 2BHATTACHAR S N, HOWARD R J, TOMOO I, et al. The effects of complexation with hydrogenated phos-pholipid on the transport of salicylic acid, diclofenac andindomethacin across snake stratum comeum [ J ]. Int J Pharm, 1992, 79:263.
  • 3国家药品标准[s]//新药转正标准(第35册),2004:170.
  • 40BOMBAREDELI E, BIANCHETTI G. Pharmaceuticaland cosmetic compositions containing complexes of fla-vanolignans with phospholipids [P]. Eur: 0, 300, 282,1989-01-25.
  • 5JANOF F, ANDREW S, YARDLEY P A, et al. Lowtoxicity drug - lipid systems [P]. US: 5, 616, 334,1997-04-01.
  • 6KIPP J E. The role of solid nanopartiele technology inthe parenteral delivery of poorly water- soluble drugs[J]. Int J Pharm, 2004, 284 : 109 - 122.

共引文献8

同被引文献30

引证文献3

二级引证文献19

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部